Larry Yost

Larry Yost is the Founder and Managing Partner of The Atticus Group, a full-service consulting firm which specializes in supporting the efforts of companies with innovative medical technologies, laboratory diagnostic tests and A.I. software-based solutions. Larry has over 35 years of combined experience with domestic and international medical device, pharmaceutical, diagnostic, and genomic services companies ranging from large international corporations to emerging companies emanating from academia.

Larry's passion is supporting efforts which lead to the development and commercialization of game changing technologies which improve patient lives and healthcare related outcomes. This includes supporting market access and commercialization activities ranging from market and technology assessment, key opinion leader (KOL) and medical society interactions, to the development and implementation of reimbursement and health economics directed strategies. Additional activities include assistance with establishing clinical evidence through the development of clinical protocols and the implementation of early feasibility clinical studies along with leading efforts to translate results from studies into peer-reviewed publications in medical journals.

Larry has experience with numerous reimbursement-related initiatives including meetings with the Centers for Medicare and Medicaid Services (CMS) and insurers in support of coverage and payment activities. He has supported initiatives which have resulted in companies successfully obtaining Medicare Transitional Pass-Through payment, New Technology APC categorization and New Technology Add-on Payment (NTAP) for their innovative medical technologies. He has also provided leadership for projects which resulted in the establishment of new Common Procedural Terminology (CPT) and Proprietary Laboratory Analysis (PLA) codes by the American Medical Association (AMA). This includes working with medical societies, when appropriate, in the pursuit of these codes. Larry has also conducted U.S. reimbursement landscape assessments for numerous companies which have included an analysis of coding, coverage, and payment policies relevant to these company’s technologies and laboratory tests along with the development of reimbursement strategies for their efforts going forward. He has also assisted companies with the successful submission of Breakthrough Device applications to the FDA. Larry also serves as a consultant to several medical technology accelerator programs and provides due diligence support to strategics, venture capital and private equity firms.

‍